Valuation
- Market cap
- 100,689,000
- Revenue TTM
- $0
- Net income TTM
- $-8,990,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 20,700
- Avg volume
- 77,318
- Day's range
- $1.98 – $2.08
- Shares out
- 49,846,000
- Stochastic %K
- 51%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $7.67
Company profile
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical st...
Show more
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 201 940 7236
- Website
- https://polaryx.com
- Address
- South Tower, 140 E Ridgewood Avenue Suite 415, Paramus, United States
Latest news
No headlines yet.
